Definitive Contract 75N93021C00054
Award Date 9/1/21
Potential Completion Date 8/31/23
Potential Value $599K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Missoula, MT 59802, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Service Contract Act
National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase I contract to Inimmune Corp, a small business biotechnology company, for the "Discovery of New Small Molecule TLR4 Agonists for the Treatment of Allergic Rhinitis". The $631,425.00 Firm Fixed Price contract has a period of performance from July 31, 2018 to July 31, 2020. Inimmune Corp, which has...
- This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases awards Inimmune Corporation $1.99 million to develop a Synthetic Adjuvant System. The contract is a result of the agency's SBIR Phase II solicitation seeking proposals for research and development to advance NIH and CDC missions, including alternatives to cell culture materials and cancer immunotherapy manufacturing. Placed in...
- This is a $5,907,864.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Inimmune Corp, a biotechnology company based in Missoula, Montana. The contract is for the development of a synthetic AS01-like adjuvant system for influenza vaccines. This is not a set-aside contract. Inimmune Corp is a promising new biotechnology company with expertise in synthetic and process...
- This $1.8 million firm fixed price contract was awarded by the National Institutes of Health National Institute of Allergy and Infectious Diseases to Inimmune Corp. of Missoula, Montana. The contract is for Phase II of the Small Business Innovation Research program topic 091 to develop a new Toll-like receptor 4 agonist for the treatment of allergic rhinitis. The research and development effort will be performed in Missoula from September 2021 through August 2023. This total small business...
- This $600,000 firm fixed price contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Adjuvax LLC of Birmingham, Alabama. The contract is being performed under SBIR Topic 106 to develop adjuvant mimics in support of the NIH and CDC's missions. The solicitation sought proposals for Small Business Innovation Research contracts across numerous technical topics aligned with improving public health. This award is set aside for total...
- This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases to Teichos Laboratories, LLC, a small business located in West Lafayette, IN. The $300,000 firm fixed price contract is for research on a novel TLR2 agonist-aluminum combination adjuvant to improve the quality and duration of the immune response. This SBIR contract was awarded under a solicitation that sought innovative...
- This is a $599,234 firm fixed price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) to Celdara Medical, a small business biotechnology company, under the Small Business Innovation Research (SBIR) program. The contract is for research to discover parasite-derived tolerogenic adjuvants, which could potentially be used in new vaccine development. Celdara Medical conducts research and...
- This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...
- This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
- The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $375,000 firm fixed price purchase order to Advanced Bioadjuvants, LLC of Omaha, Nebraska. The three-year contract, running from September 2021 through September 2024, provides a non-exclusive license to Advanced Bioadjuvants' Adjuplex adjuvant technology. This will allow the National Institute of Allergy and Infectious Diseases to manufacture cGMP grade...